Ingenuity Systems has entered a research collaboration with Covance Genomics Laboratory for next-generation sequencing (NGS) data analysis. The two companies will work together to develop new approaches, using Ingenuity’s IPA software, to obtain more actionable insights from NGS data.

With the generation of new biological interpretation tools, Covance Genomics Lab aims to help pharmaceutical clients maximize the value of their investment in NGS technologies, according to a Covance statement. IPA is designed to help mitigate the NGS data analysis bottleneck by providing the biological context necessary to move past the long lists of genes, isoforms, and variants, to help uncover those that are most critical to biology. This enables researchers to quickly get to the intended high-value results of biomarker identification, target ID and validation, understanding drug mechanism of action, and safety assessment.

“We’re delighted that Covance has selected IPA for its NGS workflows,” said Doug Bassett, Ph.D., chief scientific officer and chief technology officer, Ingenuity Systems. “We’ve been involved in several NGS collaborations recently, and our partnership with Covance represents another powerful validation of IPA’s value in the NGS space. “

“The complexity of next-generation sequencing data can be a challenge to translational science and medicine,” said Tom Turi, vice president, Science & Technology, Covance Discovery & Translational Services. “We’re confident the combination of our best-in-class genomics data and the high-quality biological content and context provided by IPA will result in the delivery of more rapid, accurate, and thorough research services for our customers.”